Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTA 201

Next Previous
X
Search
Drug Profile

GTA 201

Alternative Names: GTA-201; TCR-NK cell therapies - Glycostem

Latest Information Update: 01 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glycostem
  • Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Feb 2021 Early Research in Cancer in Netherlands (Parenteral) (Glycostem pipeline, February 2021)
  • 17 Dec 2020 Glycostem in-licenses NK cell production technology from Ghent University
  • 15 Jan 2020 Glycostem has patent protection for Ex vivo NK cell differentiation from CD34+ hematopoietic cells in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top